mifamurtide trade name mepact marketed takeda drug osteosarcoma kind bone cancer mainly affecting children young adults lethal half cases drug approved europe march mifamurtide indicated treatment highgrade nonmetastasizing resectable osteosarcoma following complete surgical removal children adolescents young adults aged two osteosarcoma diagnosed individuals europe usa per year age drug used combination postoperative multiagent chemotherapy kill remaining cancer cells improve patients chance overall phaseiii clinical trial newly diagnosed osteosarcoma patients mifamurtide combined chemotherapeutic agents doxorubicin methotrexate without cisplatin ifosfamide mortality could lowered versus chemotherapy plus placebo six years treatment patients still alive equals absolute risk reduction clinical study mifamurtide given subjects half age side effects found mild moderate nature patients experience fewer adverse events subsequent common side effects include fever vomiting fatigue tachycardia infections anaemia anorexia headache diarrhoea constipation consequently combination mifamurtide types drugs contraindicated however mifamurtide coadministered low doses nsaids evidence suggests mifamurtide interacts studied chemotherapeutics cytochrome mifamurtide fully synthetic derivative muramyl dipeptide mdp smallest naturally occurring immune stimulatory component cell walls mycobacterium species similar immunostimulatory effects natural mdp advantage longer halflife plasma pattern recognition receptor found several kinds white blood cells mainly monocytes macrophages recognises muramyl dipeptide component cell wall bacteria mifamurtide simulates bacterial infection binding activating white cells results increased production tnfÎ± interleukin interleukin interleukin interleukin cytokines well activated white cells attack cancer cells least vitro application liposomal infusion drug cleared plasma within minutes concentrated lung liver spleen nasopharynx thyroid terminal halflife hours patients receiving second treatment weeks accumulation effects mifamurtide muramyl tripeptide phosphatidylethanolamine mtppe synthetic analogue muramyl dipeptide side chains molecule give longer elimination halflife natural substance substance applied encapsulated liposomes lmtppe phospholipid accumulates lipid bilayer liposomes one method synthesis shown first based nndicyclohexylcarbodiimide dcc assisted esterification nacetylmuramyllalanyldisoglutaminyllalanine nhydroxysuccinimide followed condensation acid triethylamine different approach shown second uses nacetylmuramyllalanyldisoglutamine hydroxysuccinimide alanine introduced second step instead first drug invented cibageigy novartis early sold jenner biotherapies idm pharma bought rights developed idm pharma acquired takeda along mifamurtide june mifamurtide already granted orphan drug status us food drug administration fda european medicines agency ema followed approved european union member states plus iceland liechtenstein norway centralized marketing authorization march drug denied approval fda mifamurtide licensed ema since march httpsenwikipediaorgwikimifamurtide